Intestinal Microbiota, microbial translocation, and systemic inflammation in chronic HIV infection

Journal of Infectious Diseases

Volumn 211, Issue 1, 2015, Pages 19-27

  Dinh, Duy M ^a   Volpe, Gretchen E ^a,b   Duffalo, Chad ^a   Bhalchandra, Seema ^a   Tai, Albert K ^c   Kane, Anne V ^a   Wanke, Christine A ^a,b   Ward, Honorine D ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b Department of Public Health and Community Medicine ^*  (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dysbiosis; HIV; inflammation; microbial translocation.; microbiota

Indexed keywords

ANTIRETROVIRUS AGENT; CD14 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 1BETA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA 16S; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADULT; ALISTIPES; ANTIVIRAL THERAPY; BACTERIAL TRANSLOCATION; BARNESIELLA; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENTEROBACTERIALES; ERYSIPELOTHRIX; EXPLORATORY RESEARCH; FECES MICROFLORA; FEMALE; GAMMAPROTEOBACTERIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INTESTINE FLORA; MALE; MICROBIAL COMMUNITY; POPULATION ABUNDANCE; PROTEOBACTERIA; PYROSEQUENCING; RIKENELLACEAE; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; FECES; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; INTESTINE; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL TRANSLOCATION; BIOMARKERS; CASE-CONTROL STUDIES; FECES; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN M; INFLAMMATION; INTERLEUKIN-1BETA; INTESTINES; MICROBIOTA; RNA, RIBOSOMAL, 16S; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922414182     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu409     Document Type: Conference Paper

References (48)

1. Triant VA, Grinspoon SK. Vascular dysfunction and cardiovascular complications. Curr Opin HIV AIDS 2007; 2:299-304.
2. Currier JS, Lundgren JD. Guidelines for managing cardiovascular risk: an evolving area. Curr Opin HIV AIDS 2008; 3:205-6.
3. Deeks SG. HIV: How to escape treatment. Nature 2011; 477:36-7.
4. Hatano H. Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr Opin HIV AIDS 2013; 8:211-6.
5. van Marle G, Gill MJ, Kolodka D, McManus L, Grant T, Church DL. Compartmentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology 2007; 4:87.
6. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol 2013; 119:51-83.
7. Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol 2012; 30:149-73.
8. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10:655-66.
9. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013; 26:2-18.
10. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
11. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-33.
12. Sauce D, Larsen M, Fastenackels S, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011; 117:5142-51.
13. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201:1796-805.
14. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012; 30:759-95.
15. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027-31.
16. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohns disease revealed by a metagenomic approach. Gut 2006; 55:205-11.
17. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457:480-4.
18. Hammer HF. Gut microbiota and inflammatory bowel disease. Dig Dis 2011; 29:550-3.
19. Kim MS, Hwang SS, Park EJ, Bae JW. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 2013; 5:765-75.
20. Zhang X, Shen D, Fang Z, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 2013; 8: e71108.
21. Shim JO. Gut microbiota in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr 2013; 16:17-21.
22. Gori A, Rizzardini G, Vant Land B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the COPA pilot randomized trial. Mucosal Immunol 2011; 4:554-63.
23. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol 2008; 46:757-8.
24. Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and orderlevel 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr 2011; 57:363-70.
25. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with hiv disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra91.
26. Perez-Santiago J, Gianella S, Massanella M, et al. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. Aids 2013; 27:1921-31.
27. Volpe GE, Ward H, Mwamburi M, et al. Associations of cocaine use and HIV infection with the intestinal microbiota, microbial translocation, and inflammation. J Stud Alcohol Drugs 2014; 75:347-57.
28. Mangili A, Polak JF, Skinner SC, et al. HIV infection and progression of carotid and coronary atherosclerosis: the CARE study. J Acquir Immune Defic Syndr 2011; 58:148-53.
29. Volpe GE, Tang AM, Polak JF, Mangili A, Skinner SC, Wanke CA. Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort. J Acquir Immune Defic Syndr 2013; 64:51-7.
30. Cooley PC, Miller HG, Gribble JN, Turner CF. Automating telephone surveys: using T-ACASI to obtain data on sensitive topics. Comput Human Behav 1998; 14:195-207.
31. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7:335-6.
32. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010; 26:2460-1.
33. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics 2010; 26:266-7.
34. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007; 73:5261-7.
35. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-85.
36. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011; 12:R60.
37. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1:43-6.
38. Landmann R, Knopf HP, Link S, Sansano S, Schumann R, ZimmerliW. Human monocyte CD14 is upregulated by lipopolysaccharide. Infect Immun 1996; 64:1762-9.
39. Fukuda K, Kumagai N, Yamamoto K, Fujitsu Y, Chikamoto N, Nishida T. Potentiation of lipopolysaccharide-induced chemokine and adhesion molecule expression in corneal fibroblasts by soluble CD14 or LPSbinding protein. Invest Ophthalmol Vis Sci 2005; 46:3095-101.
40. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005; 11:225-9.
41. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226-33.
42. Pasternak BA, DMello S, Jurickova II, et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohns disease and murine colitis. Inflamm Bowel Dis 2010; 16:856-69.
43. Woo PC, Lau SK, Teng JL, Tse H, Yuen KY. Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. Clin Microbiol Infect 2008; 14:908-34.
44. Salipante SJ, Sengupta DJ, Rosenthal C, et al. Rapid 16S rRNA nextgeneration sequencing of polymicrobial clinical samples for diagnosis of complex bacterial infections. PLoS One 2013; 8:e65226.
45. Lozupone CA, Li M, Campbell TB, et al. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe 2013; 14:329-39.
46. Dillon SM, Lee EJ, Kotter CV, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia.Mucosal Immunol 2014; 7:983-94.
47. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014; 10: e1003829.
48. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011; 140:976-86.